NewsNew study: Efficacy of SARS-CoV-2 cross-vaccinations
11. January 2022by Abcalis
Abcalis® participated in a worldwide study on the efficacy of SARS-CoV-2 cross-vaccinations.
Omicron is another warning to all of us that we cannot end the pandemic locally, but only by vaccinating the entire global population in the best way possible. Fortunately for mankind, biotechnology has been able to provide numerous vaccines and medicines worldwide in a shorter time than ever before in the history of medicine. – Dr. Stefan Dübel
Read the official press release by TU Braunschweig